134 related articles for article (PubMed ID: 32519782)
21. Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma.
Inoue M; Ogasawara S; Chiba T; Ooka Y; Wakamatsu T; Kobayashi K; Suzuki E; Tawada A; Yokosuka O
J Gastroenterol Hepatol; 2017 Apr; 32(4):908-915. PubMed ID: 27787908
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of Gd-EOB-DTPA-enhanced MRI for evaluating the potential for early development of hepatocellular carcinoma after HCV eradication by direct-acting antiviral treatment.
Morimoto N; Miura K; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Murayama K; Hirosawa T; Goka R; Kunitomo N; Nakamura H; Sugimoto H; Isoda N; Yamamoto H
J Rural Med; 2019 May; 14(1):78-86. PubMed ID: 31191770
[No Abstract] [Full Text] [Related]
23. Gd-EOB-DTPA-enhanced MRI-a noninvasive and short-term assessment method for liver necroinflammation after direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C.
Li A; Wu J; Cheng J; Feng C; Liu W; Li Y; Rao H; Huang R; Zhou G; Hong N; Wang Y
Abdom Radiol (NY); 2022 Jan; 47(1):174-183. PubMed ID: 34664096
[TBL] [Abstract][Full Text] [Related]
24. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients.
Cucchetti A; D'Amico G; Trevisani F; Morelli MC; Vitale A; Pinna AD; Cescon M;
Dig Liver Dis; 2018 Feb; 50(2):156-162. PubMed ID: 29102521
[TBL] [Abstract][Full Text] [Related]
25. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K;
J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407
[TBL] [Abstract][Full Text] [Related]
26. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N
PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591
[TBL] [Abstract][Full Text] [Related]
27. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.
Toyoda H; Kumada T; Tada T; Sone Y; Maeda A; Kaneoka Y
Hepatol Int; 2015 Jan; 9(1):84-92. PubMed ID: 25788383
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C.
Yoshimasu Y; Furuichi Y; Kasai Y; Takeuchi H; Sugimoto K; Nakamura I; Itoi T
J Gastrointestin Liver Dis; 2019 Mar; 28(1):63-71. PubMed ID: 30851174
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
Kumada T; Toyoda H; Yasuda S; Tada T; Ito T; Tanaka J
J Viral Hepat; 2021 Sep; 28(9):1293-1303. PubMed ID: 34185932
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
[TBL] [Abstract][Full Text] [Related]
31. Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
Motoyama H; Tamori A; Kubo S; Uchida-Kobayashi S; Takemura S; Tanaka S; Ohfuji S; Teranishi Y; Kozuka R; Kawamura E; Hagihara A; Morikawa H; Enomoto M; Murakami Y; Kawada N
PLoS One; 2018; 13(3):e0194163. PubMed ID: 29534101
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma.
Iwamoto T; Imai Y; Kogita S; Igura T; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Seki Y; Ohashi H; Fujita N; Kudo M; Takehara T
Dig Dis; 2016; 34(6):679-686. PubMed ID: 27750237
[TBL] [Abstract][Full Text] [Related]
33. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.
Kanda T; Lau GKK; Wei L; Moriyama M; Yu ML; Chuang WL; Ibrahim A; Lesmana CRA; Sollano J; Kumar M; Jindal A; Sharma BC; Hamid SS; Kadir Dokmeci A; Mamun-Al-Mahtab ; McCaughan GW; Wasim J; Crawford DHG; Kao JH; Ooka Y; Yokosuka O; Sarin SK; Omata M
Hepatol Int; 2019 Nov; 13(6):649-661. PubMed ID: 31541423
[TBL] [Abstract][Full Text] [Related]
34. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
35. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
Singal AG; Lim JK; Kanwal F
Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
[TBL] [Abstract][Full Text] [Related]
36. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma.
Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
Ann Surg Oncol; 2019 Dec; 26(13):4566-4575. PubMed ID: 31602577
[TBL] [Abstract][Full Text] [Related]
37. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.
Wang CC; Tseng KC; Tzeng IS; Kao JH
J Formos Med Assoc; 2021 Mar; 120(3):965-973. PubMed ID: 33129621
[TBL] [Abstract][Full Text] [Related]
38. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
Myojin Y; Hikita H; Tahata Y; Doi A; Kato S; Sasaki Y; Shirai K; Sakane S; Yamada R; Kodama T; Hagiwara H; Imai Y; Hiramatsu N; Tamura S; Yamamoto K; Ohkawa K; Hijioka T; Fukui H; Doi Y; Yamada Y; Yakushijin T; Mita E; Sakamori R; Tatsumi T; Takehara T
Aliment Pharmacol Ther; 2022 Feb; 55(4):422-433. PubMed ID: 34812502
[TBL] [Abstract][Full Text] [Related]
39. The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis.
Huang P; Liu M; Zang F; Yao Y; Yue M; Wang J; Fan H; Zhuo L; Wu J; Xia X; Feng Y; Yu R
Carcinogenesis; 2018 Dec; 39(12):1497-1505. PubMed ID: 30602007
[TBL] [Abstract][Full Text] [Related]
40. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
